Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 79.15M | 83.49M | 84.45M | 77.24M | 71.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 487.17M | 487.11M | 471.09M | 438.15M | 405.21M |
| Operating Income | -487.17M | -487.11M | -471.09M | -438.15M | -405.21M |
| Income Before Tax | -460.56M | -462.44M | -445.58M | -412.95M | -382.17M |
| Income Tax Expenses | 3.64M | 2.24M | 1.73M | 890.00K | 539.00K |
| Earnings from Continuing Operations | -464.20 | -464.69 | -447.30 | -413.84 | -382.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -464.20M | -464.69M | -447.30M | -413.84M | -382.71M |
| EBIT | -487.17M | -487.11M | -471.09M | -438.15M | -405.21M |
| EBITDA | -486.75M | -486.69M | -470.69M | -437.77M | -404.87M |
| EPS Basic | -2.68 | -2.83 | -2.85 | -2.74 | -2.62 |
| Normalized Basic EPS | -1.66 | -1.76 | -1.77 | -1.71 | -1.63 |
| EPS Diluted | -2.68 | -2.83 | -2.85 | -2.74 | -2.62 |
| Normalized Diluted EPS | -1.66 | -1.76 | -1.77 | -1.71 | -1.63 |
| Average Basic Shares Outstanding | 692.76M | 658.17M | 631.00M | 606.21M | 584.83M |
| Average Diluted Shares Outstanding | 692.76M | 658.17M | 631.00M | 606.21M | 584.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |